Suppr超能文献

[肥胖与2型糖尿病(2023年更新版)]

[Obesity and type 2 diabetes (Update 2023)].

作者信息

Clodi Martin, Toplak Hermann, Resl Michael, Brix Johanna, Leitner Deborah Raphaela, Harreiter Jürgen, Hoppichler Friedrich, Wascher Thomas C, Schindler Karin, Ludvik Bernhard

机构信息

Abteilung für Innere Medizin, Konventhospital der Barmherzigen Brüder Linz, 4021, Linz, Österreich.

2. Klinisches Forschungsinstitut für kardiometabolische Erkrankungen, Johannes Kepler Universität Linz, Altenberger Straße 69, 4040, Linz, Österreich.

出版信息

Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):91-97. doi: 10.1007/s00508-023-02184-6. Epub 2023 Apr 20.

Abstract

The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and additional concomitant therapies is increasingly influenced by body weight. The importance of modern GLP‑1 agonists and dual GLP‑1 GIP agonists increases since these drugs target obesity and type 2 diabetes. Bariatric surgery is at present indicated with a BMI > 35 kg/m with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriate lifelong care concept.

摘要

体重指数(BMI)是衡量个体身体脂肪含量的一种非常粗略的指标。即使体重正常的人在肌肉量不足(肌肉减少症)的情况下也可能有过多的体脂,这就是为什么建议额外测量腰围和身体脂肪含量,例如生物电阻抗分析(BIA)。包括营养调整和增加体育活动在内的生活方式管理是预防和治疗糖尿病的重要措施。关于2型糖尿病的治疗,体重越来越多地被用作次要目标参数。抗糖尿病治疗和其他伴随疗法的选择越来越受到体重的影响。现代GLP-1激动剂和双重GLP-1 GIP激动剂的重要性日益增加,因为这些药物针对肥胖症和2型糖尿病。目前,体重指数>35kg/m²且伴有糖尿病等危险因素时,可考虑进行减肥手术,这至少可导致部分糖尿病缓解,但必须纳入适当的终身护理方案。

相似文献

1
[Obesity and type 2 diabetes (Update 2023)].[肥胖与2型糖尿病(2023年更新版)]
Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):91-97. doi: 10.1007/s00508-023-02184-6. Epub 2023 Apr 20.
3
[Obesity and type 2 diabetes].[肥胖与2型糖尿病]
Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S196-200. doi: 10.1007/s00508-016-0986-9.
5
Obesity and weight management in the elderly: a focus on men.老年人肥胖与体重管理:关注男性。
Best Pract Res Clin Endocrinol Metab. 2013 Aug;27(4):509-25. doi: 10.1016/j.beem.2013.04.012. Epub 2013 May 23.

本文引用的文献

1
Once-Weekly Semaglutide in Adolescents with Obesity.每周一次司美格鲁肽治疗肥胖青少年。
N Engl J Med. 2022 Dec 15;387(24):2245-2257. doi: 10.1056/NEJMoa2208601. Epub 2022 Nov 2.
7
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.利拉鲁肽治疗肥胖青少年的随机对照试验。
N Engl J Med. 2020 May 28;382(22):2117-2128. doi: 10.1056/NEJMoa1916038. Epub 2020 Mar 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验